Phase
Alumni
Gedea Biotech
Gedea Biotech develops pHyph ,an antibiotic-free treatment for vaginal infections. Today, bacterial vaginosis (BV) is treated with antibiotics and in a published clinical trial, pHyph shows similar cure rate as antibiotics; 82% cure rate after one week of treatment. With antibiotics, one out of two patients have a recurrent episode of BV within 90 days of treatment. The ongoing NEFERTITI-study is a placebo-controlled study with 150 patients with bacterial vaginosis, that investigates the efficacy and safety of pHyph in treatming and preventing bacterial vaginosis. pHyph intends be the first antibiotic-free treatment that effectively prevents and treats bacterial vaginosis.
Annette has a PhD in Medicine from Lund University and holds a Master’s degree in Medical Biology from Linköping University. She has long experience of project management and business development in both listed and unlisted companies also from the healthcare sector.
Did you know?
Gedea Biotech won third prize in the European Final of the EIT European Health Catapult, in the category of Biotech!
Excellence in solid material analysis
Amplify the efficacy of pharmaceutical treatments
Simplify medicine information through digital services
A "check-in buddy" for the elderly
Excellence in inhaler performance
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Digital tool for meeting an allergy doctor
Cutting-Edge Histological Solutions for Pharma Industry
Digital communication tool for titrating medicine
Mobile systems for movement analysis
Innovative solutions for better health care
GPS tracker system for elderly
Drug delivery platform
Healthtech for children with eating challenges
Digital health management tool
Short chain fatty acids can be delivered to the colon
Therapeutics after stroke
Starch pickering emulsion technology
Measuring thyroid hormone levels
Gene editing analysis solution
Cost-effective & rapid COVID-19 diagnostic test
eHealth clinic for obesity treatment
